Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Business Wire•28/09/2026•08:00 ET
0
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
– Phase 3 primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24
Get started
Create a free account to read the full story and Whiz Insights.